Phase 1: Dose Escalation for HPV-Related Squamous Cell Carcinoma
Phase-Based Progress Estimates
University of California, San Francisco, San Francisco, CA
HPV-Related Squamous Cell Carcinoma+10 More
Hyperpolarized Carbon-13 (13C) Pyruvate - Drug
You have a chance of qualifying for this trial. We made sure your application will take less than 5 minutes.
What conditions do you have?
What conditions do you have?
This phase I/II trial tests the safety, side effects, and best dose of alpelisib and whether alpelisib and carboplatin work to shrink tumors in patients with solid tumors or human papillomavirus (HPV) positive squamous cell carcinoma that has spread to nearby tissue or lymph nodes (locally advanced) or has spread to other places in the body (metastatic). Alpelisib belongs to a group of medicines called phosphatidylinositol 3-kinase (PI3K) inhibitors. This means alpelisib blocks the activity of the PI3K protein. The PI3K pathway is well known to be involved in tumor cell multiplication and survival. Blocking PI3K may reduce the ability of certain cancers to grow. Carboplatin is an anticancer drug or chemotherapy drug that binds to DNA causing damage that prevents the DNA from replicating, which prevents the cells itself from reproducing. Giving alpelisib and carboplatin may help control the disease in patients with solid tumors and HPV positive squamous cell carcinoma.
HPV-Related Squamous Cell Carcinoma
Locally Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Human Papilloma Virus-Related Carcinoma
Human Papillomavirus-Related Squamous Cell Carcinoma
Solid Tumors, Adult
PIK3CA Mutation-Related Tumors
1 of 3
Other trials for HPV-Related Squamous Cell Carcinoma
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
Patients may have received any number of lines of prior systemic therapy for locally advanced/metastatic disease.
You have a dose escalation.
You have a locally advanced or metastatic solid tumor malignancy with no curative treatment options available.
Patients will be informed of alternative therapies known to confer clinical benefit.
A positive HPV test result for any of the following HPV types (16, 18, 31, 33, 35, 39, 45, 51, 56, 58, 59, 66, or 68) in a patient with a diagnosis of anogenital warts or condylomata acuminata (warty genital lesions) or cervical intraepithelial neoplasia (CIN) 2 or 3, or both, will be sufficient to establish eligibility for the vaccine.
You have radiographic or clinical evidence of platinum resistance.
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.